Amy E Goodman Lilit Karapetyan Melissa Pugliano-Mauro Joshua E Levenson Jason J Luke
10.3389/fimmu.2021.660795
Front Immunol
2021 Mar 22;12:660795.
biomarkers case report genomics immune-related adverse events immunotherapy transplant
CC BY
https://pubmed.ncbi.nlm.nih.gov/33828564/
Allografts Antibodies, Monoclonal, Humanized / therapeutic use Antineoplastic Agents, Immunological / therapeutic use Heart Melanoma / drug therapy Melanoma / secondary Programmed Cell Death 1 Receptor / antagonists & inhibitors
Allografts Antibodies, Monoclonal, Humanized / therapeutic use Antineoplastic Agents, Immunological / therapeutic use Heart Melanoma / drug therapy Melanoma / secondary Programmed Cell Death 1 Receptor / antagonists & inhibitors Case Reports Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Aged Antibodies, Monoclonal, Humanized / administration & dosage Antineoplastic Agents, Immunological / administration & dosage Humans Immune Checkpoint Inhibitors / therapeutic use Immunotherapy Male Melanoma / diagnostic imaging Tomography, X-Ray Computed Transplant Recipients Antibodies, Monoclonal, Humanized Antineoplastic Agents, Immunological Immune Checkpoint Inhibitors Programmed Cell Death 1 Receptor pembrolizumab
PMC8019780
33828564
Case Report: Single Dose Anti-PD1 in a Patient With Metastatic Melanoma and Cardiac Allograft
2021